PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -429.90K | -757.30K | -1.46M | -819.70K | -435.70K |
| Total Depreciation and Amortization | 339.40K | 208.80K | 72.00K | 16.40K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 99.70K | 113.80K | 540.50K | 3.00K | -- |
| Change in Net Operating Assets | 290.90K | 504.10K | -93.80K | 271.10K | -44.30K |
| Cash from Operations | 300.10K | 69.40K | -939.90K | -529.20K | -480.10K |
| Capital Expenditure | -23.70K | -5.00K | -5.00K | -5.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -12.08M | -12.08M | -1.47M | 58.60K | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -12.10M | -12.09M | -1.47M | 53.60K | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -157.80K | -107.10K | -56.00K | -15.30K | -- |
| Issuance of Common Stock | 27.49M | 27.49M | 27.49M | 19.86M | 7.80K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 20.00M | 20.03M | 20.07M | 14.50M | 5.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.19M | 8.02M | 17.65M | 14.02M | -474.20K |